The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.
Richard Rammo, MD
Advertisement
Articles by Richard Rammo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program
2
Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD
3
Understanding the Mechanism and Rationale of Azetukalner to Treat Focal Epilepsy: Christopher Kenney, MD, FAAN
4
Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care
5
